Guidelines for HER2 testing in breast cancer. A national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology;Recomendación para la determinación de HER2 en cáncer de mama. Consenso nacional de la Sociedad Espanola de Anatomía Patológica (SEAP) y de la Sociedad Espanola de Oncología Médica (SEOM)

Revista Espanola de Patologia

Volumn 42, Issue 1, 2009, Pages 3-16

  Palacios, José ^a   Andreu, Xavier ^b   Calasanz, María José ^c   Concha, Ángel ^d   Corominas, José María ^e   García Caballero, Tomás ^f   López, José Antonio ^g   López Ríos, Fernando ^h   Ramón y Cajal, Santiago ⁱ   Vera Sempere, Francisco J ^j   Colomer, Ramón ^k   Martín, Miguel ^g   Alba, Emilio ^l   González, Antonio ^k   Llombart, Antonio ^m   Lluch, Ana ⁿ   Albanell, Joan ^e  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Servicio de Oncología Médica   (Spain)

^c UNIVERSITY OF NAVARRA   (Spain)

^d HOSPITAL UNIVERSITARIO VIRGEN DE LAS NIEVES   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f University Hospital of Santiago de Compostela   (Spain)

^g HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^h HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

ⁱ HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^j HOSPITAL UNIVERSITARIO LA FE   (Spain)

^k MD ANDERSON CANCER CENTER   (Spain)

^l HOSPITAL UNIVERSITARIO VIRGEN DE LA VICTORIA   (Spain)

^m HOSPITAL UNIVERSITARI ARNAU DE VILANOVA   (Spain)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

more..

Author keywords

Breast cancer; HER2 testing; Immunohistochemistry; In situ hybridization; Quality assessment; Standardization

Indexed keywords

DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2;

ARTICLE; BREAST CANCER; CANADA; CANCER SCREENING; CONSENSUS DEVELOPMENT; DIAGNOSTIC ACCURACY; GENE AMPLIFICATION; HUMAN; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; LABORATORY TEST; PRACTICE GUIDELINE; PROFESSIONAL STANDARD; PROTEIN EXPRESSION; QUALITY CONTROL; REPRODUCIBILITY; SPAIN; UNITED KINGDOM; UNITED STATES; WORK EXPERIENCE;

EID: 77953924237     PISSN: 16998855     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1699-8855(09)70147-3     Document Type: Article

References (37)

1. Akiyama T., Sudo C., Ogawara H., Toyoshima K., Yamamoto T. The product of the human c-erbB-2 gene: a 185-kilodalton glycoprotein with tyrosine kinase activity. Science 1986, 232:1644-1646.
2. Yarden Y. Biology of HER2 and its importance in breast cancer. Oncology 2001, 61(Suppl 2):1-13.
3. Yarden Y. The EGFR family and its ligands in human cancer. signalling mechanisms and therapeutic opportunities. Eur J Cancer 2001, 37(Suppl 4):S3-S8.
4. Rubin I., Yarden Y. The basic biology of HER2. Ann Oncol 2001, 12(Suppl 1):S3-S8.
5. Slamon D.J., Clark G.M., Wong S.G., Levin W.J., Ullrich A., McGuire W.L. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987, 235:177-182.
6. Ross J.S., Fletcher J.A. The HER-2/neu Oncogene in Breast Cancer: Prognostic Factor, Predictive Factor, and Target for Therapy. Oncologist 1998, 3:237-252.
7. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer. Arch Pathol Lab Med 2007, 131:18.
8. Wolff A.C., Hammond M.E., Schwartz J.N., Hagerty K.L., Allred D.C., Cote R.J., Dowsett M., Fitzgibbons P.L., Hanna W.M., Langer A., McShane L.M., Paik S., Pegram M.D., Perez E.A., Press M.F., Rhodes A., Sturgeon C., Taube S.E., Tubbs R., Vance G.H., van de Vijver M., Wheeler T.M., Hayes D.F. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25:118-145.
9. Baselga J., Tripathy D., Mendelsohn J., Baughman S., Benz C.C., Dantis L., Sklarin N.T., Seidman A.D., Hudis C.A., Moore J., Rosen P.P., Twaddell T., Henderson I.C., Norton L. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996, 14:737-744.
10. Slamon D.J., Leyland-Jones B., Shak S., Fuchs H., Paton V., Bajamonde A., Fleming T., Eiermann W., Wolter J., Pegram M., Baselga J., Norton L. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001, 344:783-792.
11. Cobleigh M.A., Vogel C.L., Tripathy D., Robert N.J., Scholl S., Fehrenbacher L., Wolter J.M., Paton V., Shak S., Lieberman G., Slamon D.J. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999, 17:2639-2648.
12. Romond E.H., Perez E.A., Bryant J., Suman V.J., Geyer C.E., Davidson N.E., Tan-Chiu E., Martino S., Paik S., Kaufman P.A., Swain S.M., Pisansky T.M., Fehrenbacher L., Kutteh L.A., Vogel V.G., Visscher D.W., Yothers G., Jenkins R.B., Brown A.M., Dakhil S.R., Mamounas E.P., Lingle W.L., Klein P.M., Ingle J.N., Wolmark N. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med 2005, 353:1673-1684.
13. Joensuu H., Kellokumpu-Lehtinen P.L., Bono P., Alanko T., Kataja V., Asola R., Utriainen T., Kokko R., Hemminki A., Tarkkanen M., Turpeenniemi-Hujanen T., Jyrkkio S., Flander M., Helle L., Ingalsuo S., Johansson K., Jaaskelainen A.S., Pajunen M., Rauhala M., Kaleva-Kerola J., Salminen T., Leinonen M., Elomaa I., Isola J. Adjuvant docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med 2006, 354:809-820.
14. Piccart-Gebhart M.J., Procter M., Leyland-Jones B., Goldhirsch A., Untch M., Smith I., Gianni L., Baselga J., Bell R., Jackisch C., Cameron D., Dowsett M., Barrios C.H., Steger G., Huang C.S., Andersson M., Inbar M., Lichinitser M., Lang I., Nitz U., Iwata H., Thomssen C., Lohrisch C., Suter T.M., Ruschoff J., Suto T., Greatorex V., Ward C., Straehle C., McFadden E., Dolci M.S., Gelber R.D. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005, 353:1659-1672.
15. Untch M., Gelber R.D., Jackisch C., Procter M., Baselga J., Bell R., Cameron D., Bari M., Smith I., Leyland-Jones B., de Azambuja E., Wermuth P., Khasanov R., Feng-Yi F., Constantin C., Mayordomo J.I., Su C.H., Yu S.Y., Lluch A., Senkus-Konefka E., Price C., Haslbauer F., Suarez Sahui T., Srimuninnimit V., Colleoni M., Coates A.S., Piccart-Gebhart M.J., Goldhirsch A. Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial. Ann Oncol 2008, 19:1090-1096.
16. Slamon D.J., Eiermann W., Robert N.J. Phase III randomized trial comparing doxorubicin and cyclophosphamide followed by docetaxel (ACT) with doxorubicin and cyclphosphamide followed by docetaxel and trastuzumab (ACTH) with docetaxel, carboplatin and trastuzumab (TCH) in HER2 positive early breast cancer patients: BCIRG 006 study. Breast Cancer Res Treat 2005, 94(supp1). abstr 1.
17. Dawood S., Gonzalez-Angulo A.M., Peintinger F., Broglio K., Symmans W.F., Kau S.W., Islam R., Hortobagyi G.N., Buzdar A.U. Efficacy and safety of neoadjuvant trastuzumab combined with paclitaxel and epirubicin: a retrospective review of the M. D. Anderson experience. Cancer 2007, 110:1195-1200.
18. Geyer C.E., Forster J., Lindquist D., Chan S., Romieu C.G., Pienkowski T., Jagiello-Gruszfeld A., Crown J., Chan A., Kaufman B., Skarlos D., Campone M., Davidson N., Berger M., Oliva C., Rubin S.D., Stein S., Cameron D. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006, 355:2733-2743.
19. Von Minckwitz G., Zielinski C., Maarteense E. al e Capecitabine vs. capecitabine + trastuzumab in patients with HER2-positive metastatic breast cancer progressing during trastuzumab treatment: The TBP phase III study (GBG 26/BIG 3-05). J Clin Oncol 2008, 26:26. (May 20 suppl; abstr 1025).
20. Tan-Chiu E., Yothers G., Romond E., Geyer C.E., Ewer M., Keefe D., Shannon R.P., Swain S.M., Brown A., Fehrenbacher L., Vogel V.G., Seay T.E., Rastogi P., Mamounas E.P., Wolmark N., Bryant J. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31. J Clin Oncol 2005, 23:7811-7819.
21. Perez E.A., Suman V.J., Davidson N.E., Sledge G.W., Kaufman P.A., Hudis C.A., Martino S., Gralow J.R., Dakhil S.R., Ingle J.N., Winer E.P., Gelmon K.A., Gersh B.J., Jaffe A.S., Rodeheffer R.J. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008, 26:1231-1238.
22. Paik S., Bryant J., Tan-Chiu E., Romond E., Hiller W., Park K., Brown A., Yothers G., Anderson S., Smith R., Wickerham D.L., Wolmark N. Real-world performance of HER2 testing- National Surgical Adjuvant Breast and Bowel Project experience. J Natl Cancer Inst 2002, 94:852-854.
23. Reddy J.C., Reimann J.D., Anderson S.M., Klein P.M. Concordance between central and local laboratory HER2 testing from a community-based clinical study. Clin Breast Cancer 2006, 7:153-157.
24. Hofmann M., Stoss O., Gaiser T., Kneitz H., Heinmoller P., Gutjahr T., Kaufmann M., Henkel T., Ruschoff J. Central HER2 IHC and FISH analysis in a trastuzumab (Herceptin) phase II monotherapy study: assessment of test sensitivity and impact of chromosome 17 polysomy. J Clin Pathol 2008, 61:89-94.
25. Hanna W., O'Malley F.P., Barnes P., Berendt R., Gaboury L., Magliocco A., Pettigrew N., Robertson S., Sengupta S., Tetu B., Thomson T. Updated recommendations from the Canadian National Consensus Meeting on HER2/neu testing in breast cancer. Curr Oncol 2007, 14:149-153.
26. Dowsett M., Hanby A.M., Laing R., Walker R. HER2 testing in the UK: consensus from a national consultation. J Clin Pathol 2007, 60:685-689.
27. Walker R.A., Bartlett J.MS., Dowsett M., Ellis I.O., Hanby A.M., Jasani B., Miller K., Pinder S.E. HER2 testing in the UK: further update to recommendations. J Clin Pathol 2008, 61:818-824.
28. Gancberg D., Di Leo A., Cardoso F., Rouas G., Pedrocchi M., Paesmans M., Verhest A., Bernard-Marty C., Piccart M.J., Larsimont D. Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites. Ann Oncol 2002, 13:1036-1043.
29. Kuukasjarvi T., Kononen J., Helin H., Holli K., Isola J. Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy. J Clin Oncol 1996, 14:2584-2589.
30. Cottu P.H., Asselah J., Lae M., Pierga J.Y., Dieras V., Mignot L., Sigal-Zafrani B., Vincent-Salomon A. Intratumoral heterogeneity of HER2/neu expression and its consequences for the management of advanced breast cancer. Ann Oncol 2008, 19:595-597.
31. Werner M., Chott A., Fabiano A., Battifora H. Effect of formalin tissue fixation and processing on immunohistochemistry. Am J Surg Pathol 2000, 24:1016-1019.
32. Haines G.K., Wiley E., Susnik B., Apple S.K., Frkovic-Grazio S., Reyes C., Goldstein L.C., Dadmanesh F., Gown A.M., Nadji M., Bracko M., Tavassoli F.A. HER2 in well differentiated breast cancer: is testing necessary. Breast Cancer Res Treat 2008, 112:551-556.
33. Bilous M., Dowsett M., Hanna W., Isola J., Lebeau A., Moreno A., Penault-Llorca F., Rüschoff J., Tomasic G., van de Vijver M. Current perspectives on HER2 testing: a review of National Testing Guidelines. Mod Pathol 2003, 16:173-182.
34. Striebel J.M., Bhargava R., Horbinski C., Surti U., Dabbs D.J. The equivocally amplified HER2 FISH result on breast core biopsy: indications for further sampling do affect patient management. Am J Clin Pathol 2008, 129:383-390.
35. Ma Y., Lespagnard L., Durbecq V., Paesmans M., Desmedt C., Gomez-Galdon M., Veys I., Cardoso F., Sotiriou C., Di Leo A., Piccart M.J., Larsimont D. Polysomy 17 in HER-2/neu status elaboration in breast cancer: effect on daily practice. Clin Cancer Res 2005, 11:4393-4399.
36. Persons D.L., Tubbs R.R., Cooley L.D., Dewald G.W., Dowling P.K., Du E., Mascarello J.T., Rao K.W., Wilson K.S., Wolff D.J., Habegger-Vance G. HER-2 fluorescence in situ hybridization. Results from the Survey Program of the College of American Pathologists. Arch Pathol Lab Med 2006, 130:325-331.
37. Tanner M., Gancberg D., Di Leo A., Larsimont D., Rouas G., Piccart M.J., Isola J. Chromogenic in situ hybridization:a practical alternative for fluorescence in situ hybridization to detect HER-2/neu oncogene amplification in archival breast cancer samples. Am J Pathol 2000, 157:1467-1472.